Urinary Incontinence (UI)
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Tabuk PharmaceuticalsSaudi Arabia - Riyadh
1 programHome -Based Kegel Trainer ExercisesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Tabuk PharmaceuticalsHome -Based Kegel Trainer Exercises
Human BioSciencesTolterodine
Clinical Trials (2)
Total enrollment: 407 patients across 2 trials
Comparison of Home Versus Clinic Kegel Rehabilitation in Women With Urinary Incontinence in the Tabuk Region
Start: Oct 2026Est. completion: Mar 2027100 patients
N/ANot Yet Recruiting
Behavior Enhances Drug Reduction of Incontinence (BE-DRI)
Start: Aug 2004Est. completion: Aug 2006307 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.